Simvastatin therapy prevents brain trauma-induced increases in β-amyloid peptide levels

Annals of Neurology

Volumn 66, Issue 3, 2009, Pages 407-414

  Abrahamson, Eric E ^a   Ikonomovic, Milos D ^a   Edward Dixon, C ^a   DeKosky, Steven T ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID BETA PROTEIN; SIMVASTATIN;

ALZHEIMER DISEASE; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BRAIN PROTECTION; CONTROLLED STUDY; DRUG EFFECT; DRUG EFFICACY; HEAD INJURY; HIPPOCAMPUS; MALE; MICROGLIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; RISK FACTOR; RISK REDUCTION; TISSUE INJURY; TRAUMATIC BRAIN INJURY;

ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; ANIMALS; BEHAVIOR, ANIMAL; BRAIN INJURIES; DISEASE MODELS, ANIMAL; HIPPOCAMPUS; HUMANS; MAZE LEARNING; MICE; NEUROPROTECTIVE AGENTS; POSTURAL BALANCE; RISK FACTORS; SIMVASTATIN; TISSUE DISTRIBUTION;

EID: 70350061584     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21731     Document Type: Article

References (63)

1. Bruns J, Hauser WA. The epidemiology of traumatic brain injury: a review. Epilepsia 2003;44(suppl 10):2-10. (Pubitemid 37280386)
2. Thurman DJ, Alverson C, Dunn KA, et al. Traumatic brain injury in the United States: a public health perspective. J Head Trauma Rehabil 1999;14:602-615. (Pubitemid 30027268)
3. Jellinger KA. Traumatic brain injury as a risk factor for Alzheimer's disease. J Neurol Neurosurg Psychiatr 2004;75: 511-512. (Pubitemid 38338800)
4. Katzman R, Terry R, DeTeresa R, et al. Clinical, pathological and neurochemical changes in dementia: a subgroup with preserved mental status and numerous neocortical plaques. Ann Neurol 1988;23:138-144. (Pubitemid 18081451)
5. Gentleman SM, Graham DI, Roberts GW. Molecular pathology of head trauma: altered β APP metabolism and the aetiology of Alzheimer's disease. In: Kogure K, Hossmann K-A, Siesjo BK, eds. Progress in brain research. Vol 96. New York: Elsevier Science Publishers BV, 1993:237-246.
6. Roberts GW, Gentleman SM, Lynch A, et al. β amyloid protein deposition in the brain after severe head injury: implications for the pathogenesis of Alzheimer's disease. J Neurol Neurosurg Psychiatr 1994;57:419-425. (Pubitemid 24118136)
7. DeKosky ST, Abrahamson EE, Ciallella JR, et al. Association of increased cortical soluble abeta42 levels with diffuse plaques after severe brain injury in humans. Arch Neurol 2007;64: 541-544.
8. Roberts GW, Gentleman SM, Lynch A, Graham DI. βA4 amyloid protein deposition in brain after head trauma. Lancet 1991;338:1422-1423.
9. Graham DI, Gentleman SM, Lynch A, Roberts GW. Distribution of β-amyloid protein in the brain following severe head injury. Neuropath App Neurobiol 1995;21:27-34.
10. Gentleman SM, Greenberg BD, Savage MJ, et al. A beta 42 is the predominant form of amyloid beta-protein in the brains of short-term survivors of head injury. NeuroReport 1997;8: 1519-1522.
11. Ikonomovic MD, Uryu K, Abrahamson EE, et al. Alzheimer's pathology in human temporal cortex surgically excised after severe brain injury. Exp Neurol 2004;190:192-203. (Pubitemid 39335718)
12. Naslund J, Haroutunian V, Mohs R, et al. Correlation between elevated levels of amyloid β-peptide in the brain and cognitive decline. JAMA 2000;283:1571-1577. (Pubitemid 30161512)
13. Cotman CW, Tenner AJ, Cummings BJ. beta-Amyloid converts an acute phase injury response to chronic injury responses. Neurobiol Aging 1996;17:723-731.
14. Hoeg JM, Brewer HBJ. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors in the treatment of hypercholesterolemia. JAMA 1987;258:3532-3536. (Pubitemid 18007514)
15. DeKosky ST. Statin therapy in the treatment of Alzheimer's disease: what is the rationale? Am J Med 2005;118:48-53.
16. Sparks DL, Sabbagh M, Connor D, et al. Statin therapy in Alzheimer's disease. Acta Neurol Scand Suppl 2006;185:78-86.
17. Sironi L, Cimino M, Guerrini U, et al. Treatment with statins after induction of focal ischemia in rats reduces the extent of brain damage. Arterioscler Thromb Vasc Biol 2003;23: 322-327. (Pubitemid 36231947)
18. Endres M, Laufs U, Huang Z, et al. Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors-mediated by endothelial nitric oxide synthase. Proc Natl Acad Sci U S A 1998;95:8880-8885. (Pubitemid 28350583)
19. Chen J, Zhang ZG, Li Y, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol 2003;53:743-751. (Pubitemid 36622511)
20. Lu D, Goussev A, Chen J, et al. Atorvastatin reduces neurological deficit and increases synaptogenesis, angiogenesis, and neuronal survival in rats subjected to traumatic brain injury. J Neurotrauma 2004;21:21-32. (Pubitemid 38141799)
21. Dixon CE, Clifton GL, Lighthall LW, et al. A controlled cortical impact model of traumatic brain injury in the rat. J Neurosci Meth 1991;39:253-262.
22. Reaume AG, Howland DS, Trusko SP, et al. Enhanced amyloidogenic processing of the beta-amyloid precursor protein in gene-targeted mice bearing the Swedish familial Alzheimer's disease mutations and a "humanized" Abeta sequence. J Biol Chem 1996;271:23380-23388.
23. Flood DG, Reaume AG, Dorfman KS, et al. FAD mutant PS-1 gene-targeted mice: increased A beta 42 and A beta deposition without APP overproduction. Neurobiol Aging 2002;23: 335-348.
24. Abrahamson EE, Ikonomovic MD, Ciallella JR, et al. Caspase inhibition therapy abolishes brain trauma-induced increases in Abeta peptide: implications for clinical outcome. Exp Neurol 2006;197:437-450.
25. Tehranian R, Rose M, Vagni V, et al. Disruption of Bax protein prevents neuronal cell death but produces cognitive impairment in mice following traumatic brain injury. J Neurotrauma 2008;25:755-767.
26. Xie Z, Culley D, Dong Y, et al. The common inhalation anesthetic isoflurane induces caspase activation and increases amyloid beta-protein level in vivo. Ann Neurol 2008;64:618-627.
27. Whalen MJ, Carlos TM, Dixon CE, et al. Effect of traumatic brain injury in mice deficient in intercellular adhesion molecule-1: assessment of histopathologic and functional outcome. J Neurotrauma 1999;16:299-309.
28. Walsh DM, Selkoe DJ. A beta oligomers - a decade of discovery. J Neurochem 2007;101:1172-1184.
29. Fassbender K, Simons M, Bergmann C, et al. Simvastatin strongly reduces levels of Alzheimer's disease β-amyloid peptides Aβ42 and Aβ40 in vitro and in vivo. Proc Natl Acad Sci USA 2001;98:5856-5861. (Pubitemid 32435732)
30. Li L, Cao D, Kim H, et al. Simvastatin enhances learning and memory independent of amyloid load in mice. Ann Neurol 2006;60:729-739. (Pubitemid 46061359)
31. Frears ER, Stephens DJ, Walters CE, et al. The role of cholesterol in the biosynthesis of beta-amyloid. Neuroreport 1999;10: 1699-1705.
32. Refolo LM, Pappolla MA, LaFrancois J, et al. A cholesterol-lowering drug reduces beta-amyloid pathology in a transgenic mouse model of Alzheimer's disease. Neurobiol Dis 2001;8: 890-899. (Pubitemid 33055603)
33. Burns M, Gaynor K, Olm V, et al. Presenilin redistribution associated with aberrant cholesterol transport enhances beta-amyloid production in vivo. J Neurosci 2003;23:5645-5649. (Pubitemid 36807842)
34. Petanceska S, DeRosa S, Sharma A, et al. Changes in apolipoprotein E expression in response to dietary and pharmacological modulation of cholesterol. J Mol Neurosci 2003;20:395-406. (Pubitemid 38146998)
35. Bales K, Verina T, Dodel R, et al. Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 1997;17:263-264.
36. Forloni G, Demicheli F, Giorgi S, et al. Expression of amyloid precursor protein mRNAs in endothelial, neuronal, and glial cells: modulation by interleukin-1. Brain Res Mol Brain Res 1992;16:128-134.
37. Buxbaum JD, Oishi M, Chen HI, et al. Cholinergic agonists and interleukin-1 regulate processing and secretion of the Alzheimer β/A4 amyloid protein precursor. Proc Natl Acad Sci U S A 1992;89:10075-10078.
38. Griffin WS, Sheng JG, Gentleman SM, et al. Microglial interleukin-1 alpha expression in human head injury: correlations with neuronal and neuritic beta-amyloid precursor protein expression. Neurosci Lett 1994;176:133-136. (Pubitemid 2119762)
39. Parvathy S, Rajadas J, Ryan H, et al. Abeta peptide conformation determines uptake and interleukin-1alpha expression by primary microglial cells. Neurobiol Aging. Epub ahead of print. PMID:18339452, doi:10.1016/j. neurobiolaging. 2008.01.011).
40. Clarke RM, O'Connell F, Lyons A, Lynch MA. The HMGCoA reductase inhibitor, atorvastatin, attenuates the effects of acute administration of amyloid-beta1 - 42 in the rat hippocampus in vivo. Neuropharmacology 2007;52:136-145. (Pubitemid 46026837)
41. Wang Q, Walsh DM, Rowan MJ, et al. Block of long-term potentiation by naturally secreted and synthetic amyloid betapeptide in hippocampal slices is mediated via activation of the kinases c-Jun N-terminal kinase, cyclin-dependent kinase 5, and p38 mitogen-activated protein kinase as well as metabotropic glutamate receptor type 5. J Neurosci 2004;24:3370-3378. (Pubitemid 38451902)
42. Nadler Y, Alexandrovich A, Grigoriadis N, et al. Increased expression of the gamma-secretase components presenilin-1 and nicastrin in activated astrocytes and microglia following traumatic brain injury. Glia 2008;56:552-567.
43. Pedrini S, Carter TL, Prendergast G, et al. Modulation of statin-activated shedding of Alzheimer APP ectodomain by ROCK. PLoS Med 2005;2:e18. (Pubitemid 40412736)
44. Cole SL, Grudzien A, Manhart IO, et al. Statins cause intracellular accumulation of amyloid precursor protein, betasecretase- cleaved fragments, and amyloid beta-peptide via an isoprenoid-dependent mechanism. J Biol Chem 2005;280: 18755-18770. (Pubitemid 41379577)
45. Lesne S, Koh MT, Kotilinek L, et al. A specific amyloid-beta protein assembly in the brain impairs memory. Nature 2006; 440:352-357.
46. Mattson MP. Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. Physiol Rev 1997; 77:1081-1132.
47. Qu C, Lu D, Goussev A, et al. Effect of atorvastatin on spatial memory, neuronal survival, and vascular density in female rats after traumatic brain injury. J Neurosurg 2005;103:695-701. (Pubitemid 43193877)
48. Mahmood A, Goussev A, Lu D, et al. Long-lasting benefits after treatment of traumatic brain injury (TBI) in rats with combination therapy of marrow stromal cells (MSCs) and simvastatin. J Neurotrauma 2008;25:1441-1447.
49. Zacco A, Togo J, Spence K, et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors protect cortical neurons from excitotoxicity. J Neurosci 2003;23:11104-11111. (Pubitemid 37548945)
50. Bosel J, Gandor F, Harms C, et al. Neuroprotective effects of atorvastatin against glutamate-induced excitotoxicity in primary cortical neurones. J Neurochem 2005;92:1386-1398. (Pubitemid 40389208)
51. He X, Jenner AM, Ong WY, et al. Lovastatin modulates increased cholesterol and oxysterol levels and has a neuroprotective effect on rat hippocampal neurons after kainate injury. J Neuropathol Exp Neurol 2006;65:652-663. (Pubitemid 44297256)
52. Seyfried D, Han Y, Lu D, et al. Improvement in neurological outcome after administration of atorvastatin following experimental intracerebral hemorrhage in rats. J Neurosurg 2004;101: 104-107. (Pubitemid 38808468)
53. Lu D, Mahmood A, Goussev A, et al. Atorvastatin reduction of intravascular thrombosis, increase in cerebral microvascular patency and integrity, and enhancement of spatial learning in rats subjected to traumatic brain injury. J Neurosurg 2004;101: 813-821. (Pubitemid 39430975)
54. McIntosh TK, Saatman KE, Raghupathi R, et al. The Dorothy Russell Memorial Lecture. The molecular and cellular sequelae of experimental traumatic brain injury: pathogenetic mechanisms. Neuropathol Appl Neurobiol 1998;24:251-267.
55. Miida T, Takahashi A, Ikeuchi T. Prevention of stroke and dementia by statin therapy: experimental and clinical evidence of their pleiotropic effects. Pharmacol Ther 2007;113:378-393. (Pubitemid 46149052)
56. Cordle A, Landreth G. 3-Hydroxy-3-methylglutaryl-coenzyme A reductase inhibitors attenuate β-amyloid-induced microglial inflammatory responses. J Neurosci 2005;25:299-307. (Pubitemid 40105600)
57. Wu H, Lu D, Jiang H, et al. Increase in phosphorylation of Akt and its downstream signaling targets and suppression of apoptosis by simvastatin after traumatic brain injury. J Neurosurg 2008;109:691-698.
58. Shabanzadeh AP, Shuaib A, Wang CX. Simvastatin reduced ischemic brain injury and perfusion deficits in an embolic model of stroke. Brain Res 2005;1042:1-5. (Pubitemid 40501309)
59. Wang H, Lynch JR, Song P, et al. Simvastatin and atorvastatin improve behavioral outcome, reduce hippocampal degeneration, and improve cerebral blood flow after experimental traumatic brain injury. Exp Neurol 2007;206:59-69. (Pubitemid 46935123)
60. Cotman CW. The beta-amyloid peptide, peptide self-assembly, and the emergence of biological activities. A new principle in peptide function and the induction of neuropathology. Ann NY Acad Sci 1997;814:1-16.
61. Lacor PN, Buniel MC, Chang L, et al. Synaptic targeting by Alzheimer's-related amyloid beta oligomers. J Neurosci 2004; 24:10191-10200. (Pubitemid 39492046)
62. Klyubin I, Walsh DM, Lemere CA, et al. Amyloid beta protein immunotherapy neutralizes Abeta oligomers that disrupt synaptic plasticity in vivo. Nat Med 2005;11:556-561. (Pubitemid 40685979)
63. Shankar G, Li S, Mehta T, et al. Amyloid-beta protein dimers isolated directly from Alzheimer's brains impair synaptic plasticity and memory. Nat Med 2008;14:837-842.